Thermo Fisher Scientific (NYSE:TMO) PT Raised to $615.00

Thermo Fisher Scientific (NYSE:TMO) had its price objective hoisted by Barclays from $590.00 to $615.00 in a report released on Thursday morning, Benzinga reports. The brokerage currently has an equal weight rating on the medical research company’s stock.

Several other research firms have also recently weighed in on TMO. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an outperform rating on the stock in a research report on Thursday. Raymond James increased their price target on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an outperform rating in a research report on Thursday, February 1st. HSBC increased their price target on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a buy rating in a research report on Wednesday, April 17th. JPMorgan Chase & Co. increased their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an overweight rating in a research report on Thursday. Finally, Evercore ISI raised their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an outperform rating in a report on Thursday, April 4th. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of Moderate Buy and a consensus target price of $606.76.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $572.10 on Thursday. Thermo Fisher Scientific has a 52 week low of $415.60 and a 52 week high of $603.82. The company has a market cap of $218.38 billion, a PE ratio of 36.70, a price-to-earnings-growth ratio of 2.44 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The firm’s 50-day simple moving average is $573.08 and its two-hundred day simple moving average is $529.36.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. Research analysts predict that Thermo Fisher Scientific will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.01%.

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares of the company’s stock, valued at approximately $660,192.79. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its position in shares of Thermo Fisher Scientific by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock valued at $16,582,503,000 after purchasing an additional 180,618 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Thermo Fisher Scientific by 0.4% in the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock worth $6,285,838,000 after buying an additional 50,736 shares during the period. Capital Research Global Investors lifted its holdings in shares of Thermo Fisher Scientific by 6.9% in the 4th quarter. Capital Research Global Investors now owns 7,989,614 shares of the medical research company’s stock worth $4,240,824,000 after buying an additional 517,137 shares during the period. Norges Bank purchased a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth $2,909,524,000. Finally, Northern Trust Corp lifted its holdings in shares of Thermo Fisher Scientific by 2.6% in the 3rd quarter. Northern Trust Corp now owns 3,929,225 shares of the medical research company’s stock worth $1,988,856,000 after buying an additional 99,377 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.